Buccal Clonazepam versus Intravenous (I/V) Midazolam for Management of Acute Breakthrough Seizure –A Randomized Controlled Trial

Seizures are one of the commonest neurological symptoms seen in children. Recurrent seizures could ensue from epilepsy, febrile seizures, provoked seizures, drug inefficacy or with, or due to unknown or systemic illnesses [1]. A breakthrough seizure is an epileptic seizure that occurs, despite the use of anticonvulsants that have otherwise successfully prevented seizures in the patient. Breakthrough seizures may be more dangerous than nonbreakthrough seizures as they are less expected by the patient. Epileptics with a higher intensity of seizures are more likely to suffer from a breakthrough seizure. Rates of breakthrough seizures vary; studies have shown the rates of breakthrough seizures ranging from 11-37 % [2,3].